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Background: Myocardial crypts are discrete clefts or fissures in otherwise compacted myocardium of the left
ventricle (LV). Recent reports suggest a higher prevalence of crypts in patients with hypertrophic cardiomyopathy
(HCM) and also within small samples of genotype positive but phenotype negative relatives. The presence of a
crypt has been suggested to be a predictor of gene carrier status. However, the prevalence and clinical significance
of crypts in the general population is unclear. We aimed to determine the prevalence of myocardial crypts in a
large cohort of subjects using clinical cardiovascular magnetic resonance (CMR).
Methods: Consecutive subjects referred for clinical CMR during a 12-month period (n = 1020, age 52.6 ± 17, males:
61%) were included. Crypts were defined as >50% invagination into normal myocardium and their overall prevalence,
location and shape was investigated and compared between different patient groups.
Results: The overall prevalence of crypts was 64/1020 (6.3%). In a predefined ‘normal’ control group the prevalence
was lower (11/306, 3.6%, p = 0.031), but were equally prevalent in ischemic heart disease (12/236, 5.1%, p = n/s) and
the combined non-ischemic cardiomyopathy (NICM) groups (24/373; 6.4%, p = n/s). Within the NICM group, crypts
were significantly more common in HCM (9/76, 11.7%, p = 0.04) and hypertensive CM subjects (3/11, 27%, p = 0.03).
In patients referred for CMR for family screening of inherited forms of CM, crypts were significantly more prevalent
(10/41, 23%, p < 0.001), including a smaller group with a first degree relative with HCM (3/9, 33%, p = 0.01).
Conclusion: Myocardial crypts are relatively common in the normal population, and increasingly common in HCM and
hypertensive cardiomyopathy. Crypts are also more frequently seen in normal phenotype subjects referred because of
a family history of an inherited cardiomyopathy and HCM specifically. It is uncertain what the significance of crypts are
in this group, and because of variability in the imaging protocols used and their relative frequency within the normal
population, should not be used to clinically stratify these patients. Prospective studies are required to confirm the
clinical significance of myocardial crypts, as their significance remains unclear.
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Cardiovascular magnetic resonance (CMR) is recognized
as the gold standard for in vivo determination and quan-
tification of cardiac volumes, mass and dimensions [1-3],
based on excellent spatial resolution and strong contrast
between blood and myocardium. However, with increas-
ingly advanced imaging the paradoxical dilemma of identi-
fying novel findings with unknown clinical significance
becomes increasingly problematic [4].
Myocardial crypts are slit-like blood-filled invaginations
within the compacted LV myocardium, and have also
previously been referred to as clefts and fissures. Although
they were first identified macroscopically at autopsy in
cases of HCM [5] they have subsequently been reported
in a wide variety of cardiac diseases [6,7], as well as nor-
mal control subjects [8-10]. Microscopically described in
the context of HCM, crypts are seen to extend inwards
from the endocardial surface, lined by endocardium end-
ing in a blind pocket [9] within areas of marked fascicular
disarray [10]. Evidence of any clinical significance remains
elusive and crypts are generally thought to represent a
normal variant.
Recently however, myocardial crypts have been associ-
ated with HCM gene mutations. In a recent retrospective
study (n = 300) patients with phenotypic HCM and a
known disease-causing mutation were significantly more
likely to have crypts, than in patients with phenotypic
HCM without a known disease-causing mutation [11]. In
patients without phenotypic HCM, but known to carry
disease-causing mutations (‘carriers’) small studies have
identified a high prevalence of myocardial crypts [8,12,13],
suggesting a potential role of crypts to identify patients
who should proceed to genetic testing.
There are a number of inconsistencies in the method-
ology of these studies, including the specific criteria for
identifying crypts (whether the historical 50% penetration
[8,12,14,15], or more recent 30% penetration [7] is used)
and the need for additional non-standard views [7]. In the
present study we undertook a systematic review to test
the utility of various diagnostic criteria and to estimate the
prevalence of crypts using CMR in a sufficiently large and
relatively unbiased cohort.
Methods
Consecutive subjects presenting during a 12-month period
to the clinical CMR service of the Department of Cardio-
vascular Imaging at King’s College London were included
encompassing a broad range of clinical backgrounds, from
a mixed 2–3 million general population. Exclusion criteria
for all subjects were the generally accepted contraindica-
tions to CMR (implantable devices, cerebral aneurysm
clips, cochlear implants, severe claustrophobia) or history
of renal disease with a current estimated glomerular filtra-
tion rate <30 mL/min/1.73 m2. The study protocol wasreviewed and approved by an institutional ethics commit-
tee and written informed consent was obtained from all
participants. Subjects with no evidence of heart disease
on CMR (normal LV volumes, function and mass, and
absence of Late Gadolinium Enhancement (LGE), who
were normotensive, took no medication and had no
family history of CM or sudden cardiac death served as
a ‘control’ comparator group. Subjects who did not fulfill
these criteria were divided into the following CMR groups;
ischemic heart disease (IHD) with evidence of ischemic
type scar on CMR and/or a positive stress test, NICM
with evidence of increased left ventricular end-diastolic
volume indexed to body surface area and reduced ejection
fraction, compared with published reference ranges nor-
malized for age and sex [14], and no ischemic scar or
positive stress test, and a normal phenotype group who
were referred for CMR screening due to a family history
of an inherited CM (FHCM). This screening group con-
sisted of patients with a first degree relative with a
proven or suspected inherited CM (HCM, ARVC and
DCM). The non-ischemic CM group was further sub-
classified into dilated CM (DCM), hypertensive CM
(HtCM), inflammatory CM (including myocarditis, sar-
coidosis, systemic inflammatory conditions), HCM, ar-
rhythmogenic right ventricular CM (ARVC), congenital
heart disease, pericardial disease, and other (non ischemic
CMP without possible further classification). Patients
who did not fulfill any of the above criteria are grouped
together in a general ‘other’ group (such as patients with
coronary risk factors with normal CMR, or an unknown
clinical background).
Image acquisition
CMR studies were performed with the patient supine
using a clinical 1.5 Tesla (T) or 3 T scanner (Philips Health-
care, Best, Holland) equipped with advanced cardiac
package and a 32-channel coil. Standardized imaging
protocols were performed in line with the clinical questions
following the standardised protocols [15]. Standardized
patient specific planning volumetric cavity assessment was
obtained by whole-heart coverage of gapless short-axis
slices (SAX). Thereafter, cine-images of 3 long-axis views
(LAX: 4-chamber, 2-chamber and 3-chamber view) and
transverse axial views were acquired. All cine-images were
acquired using a balanced steady-state free precession
(SSFP) sequence in combination with parallel imaging
(SENSitivity Encoding, factor 2) and retrospective gating
during a gentle expiratory breath-hold (TR/TE/flip-angle:
3.4 ms/1.7 ms/60°, spatial resolution 1.8×1.8×8 mm).
LGE imaging was performed in corresponding views in
all subjects using a mid-diastolic inversion prepared 2-
dimensional gradient echo sequence (echo time/repetition
time/flip angle 2.0 ms/3.4 ms/25°, spatial resolution
1.8 × 2 × 10 mm reconstructed to 1.8 × 1.8 × 8 mm, with
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trast injection (gadobutrol, 0.2 mmol/kg body weight).
Imaging datasets with complete cine imaging and LGE
imaging were included in the further analysis.
Image analysis
All routine CMR analysis was performed using commer-
cially available software (ViewForum, Extended Workspace,
Philips Healthcare, Holland) and following societal post-
processing guidelines [15-17]. Endocardial LV borders were
manually traced at end-diastole and end-systole. The papil-
lary muscles were included as part of the LV cavity volume.
LV end-diastolic (EDV) and end-systolic (ESV) volumes
were determined using Simpson’s rule. Ejection fraction
(EF) was computed as EDV-ESV/EDV. LV mass was calcu-
lated as the difference between endocardial and epicardial
contour area multiplied by the specific gravity of myocar-
dium (1.05 g/mL). All volumetric indices were normalized
to body surface area.
Definition of crypts and analysis
Crypts were defined visually as a structural abnormal-
ities consisting of narrow, deep blood-filled invaginations
considered on cine viewing to penetrate >50% of the
thickness of adjoining myocardium during diastole [9],
perpendicular (45–135 degrees) to the endocardial border
of otherwise normal compacted myocardium and evidence
of subtotal or total obliteration during systole by surround-
ing tissue [7]. Because of the recent inconsistency in the
classification of myocardial crypts as either 30 or 50%, we
analyzed crypts > 50% in-line with the bulk of the available
studies, but also recorded crypts in the 25-50% for further
comparison. Their location was recorded based upon the
17-segment heart model recommended by the American
Heart Association [17], and because recent studies have re-
ported only inferior/ inferoseptal crypts [13], a pre-specified
sub-analysis of this group was performed (defined as
segments 3,4,9,10,15). The overall appearance of the crypts
were subdivided into 3 groups; triangular (v shaped), a
width of less than half the height (I shaped), or little differ-
ence in width and height (u shaped). Two independent
observers confirmed the presence of all the crypts.
An assessment of inter-observer variability was per-
formed using a random selection of 20-blinded cases.
Concordance of crypts identification, as well as depth,
position, shape and number were all assessed.
Statistical analysis
All statistics were performed using SPSS Statistics, version
20 (IBM SPSS, New York, USA). Only crypts with >50%
invagination into adjoining myocardium were considered
in the main statistical analysis. Crypts with 25-50%
invagination are reported and analysed additionally.
Continuous data were compared using a student t test(or one-way ANOVA when comparing multiple groups).
For categorical data a chi-squared test was performed,
with a Fishers exact test when expected frequencies were
less than 5. A Fliess’ Kappa calculation was used to test
inter-observer variability. Data are presented as means
with standard deviations (Mean ± SD) and a p-value of less
than 0.05 was considered significant.
Results
CMR studies of 1020 consecutive patients (age 52.6 ± 17,
male 61%) were analysed and subject characteristics are
presented in Table 1. The clinical backgrounds were
available for 963 subjects. The most common referral
group had a diagnosis of non-ischemic cardiomyopathy
(37%), followed by patients who fulfilled our ‘control’
group criteria (30%), then ischemic cardiomyopathy (23%).
Myocardial crypts (defined as >50% penetration) were
identified in 64 out of 1020 patients (6.3%) (Table 2).
The inter-observer agreement in identifying crypts that
fulfilled the 50% criteria was very strong (K = 0.92). 62 of
the crypts are presented in Figure 1.
Age and gender were not significantly different between
the group with and without crypts. Myocardial crypts
were found significantly less frequently in our ‘control’
group compared to the overall cohort (3.6% vs 6.3%,
p < 0.031). They were found more frequently in the
phenotypic HCM group (9/76, 12%, p < 0.044) and in the
hypertensive CM group (3/11, 27%, p < 0.025), where they
were all located in segment 4. The prevalence of crypts
in the other NICM or ICM groups was not statistically
different (Figure 2).
Crypts were also found more commonly in the pheno-
typic normal group referred for screening based on a FH
of inherited cardiomyopathy (10/41, 23%, p < 0.001) com-
pared to the overall group. Including the small subgroup
of 9 patients referred with a 1st degree relative with a clin-
ical HCM diagnosis (3/9, 33%, p < 0.014) (Figure 2), again
these were all located in segment 4 (AVI videos of these
are included as on-line Additional files 1, 2, and 3). Of
note, the only patient with a known disease-causing muta-
tion did not have a myocardial crypt.
When crypts of >25% myocardial penetration are
grouped together, the overall prevalence is 8.8% (90/
1020), with the same trend between the diagnostic groups
(less prevalent in the control group (3.6%, p < 0.001), more
prevalent in the HCM group (13%, p = 0.1), HtCM (27,
p = 0.68), FHCM (28%,p < 0.001) and the subgroup of the
FHCM with HCM relatives (33%, p = 0.04). The smaller
crypts were more difficult to differentiate from normal
endocardial borders and papillary muscles, and there was
less concordance between reviewers (K = 0.72).
Multiple crypts were found in 11 patients (1.1%). These
were mainly in the NICM group (7/374, 1.8%, p = 0.1), but
this was not statistically significant compared to the












Age years (mean, range, SD) 44.7, 17–82, 16.1 65.3, 30–90, 11.2 54.5, 16–87, 16.0 42.4, 21–75, 15.8 48.7, 22–83, 15.7 <0.01
Gender (male) 165 (53.9%) 179 (75.8%) 222 (59.6%) 20 (46.5%) 31 (50%) <0.01
EDV mL (SD) 79.5 (14.4) 101.4 (39.0) 94.8 (34.8) 78.9 (14.4) 75.2 (13.7) <0.01
ESV mL (SD) 31.8 (9.6) 51.5 (4.9) 52.4 (35.6) 32.4 (7.7) 31.1 (8.2) <0.01
EF% (SD) 60.6 (6.0) 46.8 (16.6) 49.2 (17.5) 59.1 (6.2) 58.9 (7.3) <0.01
Mass g (SD) 54.8 (17.2) 66.2 (22.2) 73.3 (24.3) 51.5 (14.2) 55.3 (17.5) <0.01
ICM- ischemic cardiomyopathy, NICM- non-ischemic cardiomyopathy, EDV – end diastolic volume, ESV – end-systolic volume, EF – ejection fraction.
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more than 2 crypts were identified, only the most promin-
ent 2 were analyzed. By far the most common location
for myocardial crypts was in the basal inferior segments
(segment 4 – 52/ 75 (69%), other inferior segments 9/75
(12%), non-inferior segments 14/75 (19%). U shaped
crypts (36/75) and V shaped crypts (28/75) were the
most common appearance (i shaped 11/75).
48 cases with inferior crypts (4.7%) were identified.
Like the overall crypt group, inferior crypts were more
common in the phenotypic normal group referred for
screening for inherited cardiomyopathy (16%, p = 0.003),
including the group referred for HCM screening (33%,
p = 0.006). There was a non-significant trend for it to be
more common in the overall NICM group (5.9%, p =Table 2 Crypt prevalence
Overall prevalence n- (%)
Age- years (SD)
Gender male/female (% male)











Phenotype negative inherited cardiomyopathy family members (including HC
Phenotype negative HCM family members
‘Control’ group
Unknown
Distribution of Crypts by gender, age and clinical diagnosis. Crypts >50% invaginati
ICM – ischemic cardiomyopathy, NICM – non-ischemic cardiomyopathy, DCM – dilated
cardiomyopathy, ARVC – arrhythmogenic right ventricular cardiomyopathy. T-tests per0.09), hypertensive CM group (27%, p = 0.012) and the
HCM group (12%. P = 0.02), but less common in the
‘control’ group (2.6%, p = 0.03).
Myocardial crypts were most commonly identified
from the LGE LAX view (64/75). The next best view was
the pre-contrast cine LAX (60/75). When identifying a
crypt using the LGE imaging it is very helpful to have a
cine of the same crypt to differentiate blood pool inva-
gination of the myocardium from scar.
Volumes and systolic function
The mean EDV, ESV and SV were all better in the group
with myocardial crypts compared to the group without
(EDV 90.2 ± 31 vs 83.2 ± 25.0 mls, p = 0.09; ESV 45.9 ± 32






927 (90.9%) 64(6.3%) 29 (2.8%)
52.5 (17.0) 53.23 (16.2) 54.9 (16.7)
565/362 (61%) 42/22 (66%) 15/14 (52%)
214 (90.7%) 12 (5.1%) 10 (4.2%)
342 (91.0%) 24 (6.4%) 10 (2.7%)
120 (95.3%) 5 (3.9%) 1 (0.8%)
8 (73%) 3 (27%)* 0
79 (89.8%) 5 (5.7%) 4 (4.5%)
67 (87%) 9 (11.7)* 1 (1.3%)
2 (50%) 0 2 (50%)
4 (67%) 0 2 (33%)
7 0
55 2
M) 31 (72.1%) 10 (23.3%)** 2 (4.7%)
6 (67%) 3 (33%)* 0
295 (96%) 11 (3.6%)*
45 (79%) 5 (8.8%) 7 (12.2%)
on into surrounding normal myocardium. Partial crypts 25-50% invagination.
cardiomyopathy, HtCM – hypertensive cardiomyopathy, HCM – hypertrophic
formed between crypts > 50% group and no crypt group. *p < 0.05, **p < 0.01.
Figure 1 Myocardial crypts idenitifed from 1020 consecutive CMR cases. Examples of Myocardial crypts (>50% penetration) with white
arrows indicating location.
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ferences were only apparent in the ICM group (EDV
p = 0.053, ESV 0.02, EF 0.002).Discussion
To the best of our knowledge, this is the largest study to
date to examine the prevalence of myocardial crypts using
CMR within a broad clinical referral based population.
We demonstrate that the overall prevalence of myocardialcrypts is 6.3% in our cohort of over 1000 patients. We fur-
ther show that although crypts are found less frequently
in our control group, they are still present in 3.6% of ap-
parently normal cases and they are by no means a rare
phenomenon or specific for myocardial disease. Crypts
were found significantly more frequently in patients with
hypertensive cardiomyopathy and hypertrophic cardio-
myopathy, in-keeping with previous studies [7,18,19].
Of particular interest, subjects who were phenotypic
normal referred for CMR because of a family history of
Figure 2 Prevalence of myocardial crypts by underlying cardiac diagnosis. ICM – ischemic cardiomyopathy, NICM – non-ischemic
cardiomyopathy, HCM – hypertrophic cardiomyopathy, HtCM – hypertensive cardiomyopathy, FH – family history of cardiomyopathy.
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of myocardial crypts, including a small subset with a 1st
degree relative with confirmed HCM.
Advances in cardiac imaging have led to novel findings
and new diagnoses. However, identifying and differenti-
ating new subtle pathological findings from physiological
variation can be a challenge. Crypts were initially noted
during post mortem analysis of patients with HCM [5],
and represented a pathological manifestation with crypts
occurring within areas of marked fascicular disarray
[9,10]. Subsequently, with increasingly sophisticated
invasive imaging techniques crypts have been identified
in-vivo in multiple other cardiac pathologies as well as
in normal hearts. The improved spatial resolution has
improved our ability to differentiate deep crypts fromFigure 3 Comparison between myocardial crypts and left ventricular
with “spongy” appearance of hyper-trabeculation overlying thinned compa
penetrate into normal myocardium.certain disease states, such as left ventricular non-
compaction (Figure 3), aneurysms and diverticulum
[20]. However, it has also increased its recognition
within the normal population, in where it is unlikely to
be the manifestation of myocardial disarray but rather
normal physiological variation.
Our overall prevalence of crypts was similar to other
recent studies, reporting a prevalence of 6-7% in the
general population and controls using the >50% criteria
[8,12,13], and 12% when crypts >30% were included [7].
The increased prevalence of crypts in both hypertensive
cardiomyopathy [12] and hypertrophic cardiomyopathy
[13] is also in concordance with prior published reports.
A recent study has identified crypts more commonly in
HCM patients with a known disease-causing mutationnon-compaction. Left – A case of left ventricular non-compaction
cted myocardium. Right (top and bottom) – prominent crypts seen to
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ing [11], possibly explaining the variability in reported
HCM crypt prevalence seen in the literature. A previously
reported increase seen in myocarditis was not apparent in
our cohort [13].
The increased prevalence of myocardial crypts in patients
referred because of a family history of a presumed inherited
cardiomyopathy is a very interesting finding. There has
been a very high proportion of crypts reported in subjects
who are phenotypic normal with proven gene-causing
mutations (‘carriers’). Recent studies by Germans et al.
(n = 13, crypt prevalence 81%) [18], Brouwer et al. (n = 43,
prevalence 70%) [7] and Maron et al. (n = 31, prevalence
61%) [19], have suggested that the presence of crypts in
patients with an otherwise normal CMR and a family
history of HCM could be a marker of ‘carrier’ status, and
may have future potential to guide genetic testing. Our
cohort of family screening referrals represented a rela-
tively heterogeneous group in comparison, consisting of
9 patients referred with a first degree relative with a
confirmed diagnosis of HCM (either genetically or clinically
diagnosed), and 32 patients in whom there was a relative
with either suspected HCM, or unexplained cardiac death
in which an undiagnosed inherited cardiomyopathy was
considered likely. Genetic testing was performed in only
5 of these relatives. This heterogeneity will likely explain
why our prevalence of crypts was not as high as in these
previous studies, it does however represent a general
population referred for CMR in which there was an im-
portant but limited role in diagnosing HCM and screen-
ing of family members with HCM. Our study was
designed to represent a real-world clinical referral group
as opposed a tightly pre-selected research group, but
supports the notion that whilst the presence of crypts is
not entirely rare in the normal population there are
certain clinical considerations within particular referral
groups, albeit with caution.
An additional reason why our frequency of crypts in
this group is not as high as in some reports is because of
the use of additional imaging planes used in some studies.
The vast majority of the crypts identified in this study
were in the inferoseptal segments, particularly the basal
inferior segments. The use of additional long-axis imaging
through the inferoseptum is likely to further improve the
identification of crypts in this area, with its use doubling
the sensitivity of crypt detection in 1 study looking at
HCM mutation carriers [7]. However, whilst it may be
feasible to perform these extra views within prespecified
groups, it is unlikely to be warranted in the majority of
patients whilst the clinical significance of crypts remains
unclear. Our findings support the notion that crypts are
found more frequently in patients with a family history of
HCM, and in these patients additional long-axis imaging
may be warranted.The improved spatial resolution has been credited with
improving the ease of identifying crypts [19]. Traditionally
crypts have been arbitrarily classified as >50% penetration
into the myocardium [5], however a recent study has used
an alternative 30% criteria based on the premise that this
is considered abnormal to a substantial number of cardiol-
ogists [7]. Our clinical experience during this study was
that we were a lot less confident in differentiating the
smaller crypts (25-50%) from normal endocardial trabe-
culation, even though our intra-observer variability for
this group remained relatively strong (K = 0.72). We would
advocate that the 50% criteria are adopted in future studies
for the purposes of consistency.
Furthermore, crypts were identified more frequently in
patients with greater EF and smaller EDV and ESV inde-
pendent of underlying cardiac diagnosis. This is similar
to another recent study, which found lower EDV and
greater stroke volume and ejection fraction in the group
with myocardial crypts [13]. This phenomenon initially
appears rather paradoxical, given the previous associations
with myocardial disarray and disease. However, when we
analyze each diagnostic group separately we find this
difference only in the ischemic cardiomyopathy group. We
hypothesize that the explanation for this finding is that in
patients with thinned remodeled ischemic cardiomyopathy,
which may be hypo- or akinetic the identification of myo-
cardial crypts are more difficult. This mechanism would
also suggest that crypts are easier to detect in subjects with
LV hypertrophy, such as in patients with HCM and HtCM.
Limitations
A few limitations apply to this study. Inclusion criteria
relied on clinical referral in line with practice recom-
mendations for clinical CMR; therefore, the inclusion of
patients is not unselected and not necessarily represen-
tative of the general population. As such, although we
are able to provide an insight into the prevalence of
crypts in a large cohort with broad clinical questions, this
may not be representative of the true normal population.
However, our control group was also composed of a sub-
group of normal healthy volunteers (n = 20) in whom the
prevalence of crypts was similar (10%), and as such we
believe that our control group remains representative.
The greatest limitation is the absence of genome ana-
lysis available for our patients; hence we are unable to
fully compare our findings with centers where genome
analysis is routinely available. However, our study design
reflects routine clinical practice and provides information
on the prevalence of crypts in a less well defined more
representative group of patients.
Conclusion
Despite recent interest in the clinical significance of myo-
cardial crypts, especially in the context of HCM mutation
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Crypts were found in 3.6% of our ‘normal’ subjects, and
6.3% overall. As such, they are a relatively common
finding and are not specific for disease. They do how-
ever occur more frequently in certain diseases, such as
HCM and hypertensive cardiomyopathy. In our study,
they did occur more frequently in patients referred
because of a family history of HCM and non-specific
inherited cardiomyopathy with an otherwise normal
CMR. This was a very broadly-selected real-world group
and suggests that whilst the presence of crypts is not
specific for HCM/ cardiomyopathy ‘carrier’ status, their
appearance does have potential implications in such a
pre-defined patient group. Future implications may in-
clude directing follow-up screening and genetic testing.
However, prospective outcome data, both within the
general population and HCM ‘carrier’ groups are required
before clinical implications can be drawn. Because of the
variability in sequences performed, and the subsequent
variation in crypt prevalence within the HCM ‘carrier’
group we do not advocate using the presence of crypts to
directly impact upon the choice of genetic screening on
the current evidence.
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Additional file 1: Caption: Myocardial Crypt identified in patient
with hypertrophic cardiomyopathy.
Additional file 2: Caption: Myocardial Crypt identified in patient
with hypertrophic cardiomyopathy.
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SAX: Short-axis; LAX: Long axis; SSFP: Steady state free processing; EDV: End
diastolic volume; ESV: End systolic volume.
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